CBD Regulation Delay Sparks Congressional Inquiry into FDA’s Responsibility on Hemp-Derived Products
The Food and Drug Administration’s (FDA) refusal to establish regulations permitting the marketing of hemp-derived CBD products has caught the attention of a congressional committee. A hearing is scheduled for July 27 before the House Oversight and Accountability Subcommittee on Health Care and Financial Services. The focus of the hearing, entitled “Hemp in the Modern World: The Years long Wait for FDA Action,” aims to address concerns raised by bipartisan and bicameral lawmakers over the FDA’s neglect in ensuring the safety of legalized hemp-derived products.
Investigating the FDA’s Inaction
Chairwoman Lisa McClain (R-MI) expressed her dismay in a press release, stating that the FDA has failed to carry out its regulatory responsibilities concerning CBD and other areas of jurisdiction. The absence of clear regulations could lead to unsafe products finding their way into the market while credible and safe CBD products are held back. The committee aims to investigate the reasons behind the FDA’s decision to disregard CBD regulation and determine whether the agency is seeking additional authority and resources from Congress.
Congressional Criticism and Legislation
Representative James Comer (R-KY), who chairs the full committee, has been a vocal critic of the FDA since the agency’s announcement in January that it would not be developing CBD regulations. The FDA cited a lack of available pathways and indicated that congressional action would be necessary. Responding to this, Senators Ron Wyden (D-OR), Rand Paul (R-KY), Jeff Merkley (D-OR), and Representative Earl Blumenauer (D-OR) reintroduced the Hemp Access and Consumer Safety Act. The bill aims to eliminate the regulatory barriers preventing the FDA from permitting CBD sales in the food supply and as dietary supplements.
The Hemp Access and Consumer Safety Act
The proposed Hemp Access and Consumer Safety Act seeks to exempt “hemp, hemp-derived cannabidiol, or a substance containing any other ingredient derived from hemp” from specific federal restrictions while allowing authorities to impose necessary labeling and packaging rules. The legislation aims to create a more definitive framework for CBD regulations, which would benefit both consumers and hemp producers. Supporters, including Senators Wyden, Paul, and Merkley, emphasized the importance of updating CBD regulations to ensure safe access for consumers and bolster the growth of hemp farming businesses.
Congressman Comer’s Investigation and Formal Hearing
As early as April, Congressman Comer made it clear that his committee would be launching an investigation into the FDA’s lack of action on CBD regulations. He even requested relevant documents from the FDA regarding its decision-making process. Now, with the hearing before the House Oversight and Accountability Subcommittee on Health Care and Financial Services fast approaching, lawmakers are poised to address the FDA’s inaction regarding CBD regulation.
Industry Testimony at the Hearing
The U.S. Hemp Roundtable announced that Jonathan Miller, their general counsel, will be among the witnesses testifying at the congressional hearing. His testimony is expected to provide valuable insights into the impact of the FDA’s regulatory delay on hemp-derived products and the potential consequences for consumers and the industry as a whole.
In conclusion, the pending congressional hearing on the FDA’s delay in regulating hemp-derived CBD products has raised concerns about consumer safety and market access. The proposed Hemp Access and Consumer Safety Act represents lawmakers’ efforts to fill the regulatory gap and provide clarity in this rapidly growing industry. As the hearing approaches, all eyes are on the FDA’s response and the potential implications for the hemp and CBD market.
